SCP 34: WIPO patent committee charts a course for the examination of voluntary and compulsory licensing practices during the Covid-19 pandemic

On Friday, 30 September 2022, at the Geneva headquarters of the World Intellectual Property Organization (WIPO), the 34th session of Standing Committee on the Law of Patents (SCP) adopted a future work plan for WIPO’s patent committee on patents and… Continue Reading →

166 contracts disclosed in SEC filings include authorizations to use U.S. patents without consent from patent holders

On 12 October 2022, Knowledge Ecology International (KEI) published a briefing note on the U.S. federal government FAR 52.227-1 authorizations (for non voluntary use of patents) disclosed in 166 SEC exhibits. KEI Briefing Note 2022:2, Federal government FAR 52.227-1 authorizations… Continue Reading →

Informal, focused consultations (IFCs) on WHO’s pandemic treaty to address: 1) legal matters, 2) equity, 3) IP and access to pandemic response products, and 4) One Health, AMR, Climate and Zoonosis

As part of ongoing WHO negotiations on a pandemic treaty, the WHO secretariat is set to convene four informal, focused consultations (IFCs) on the following themes: 1) legal matters, 2) operationalizing and achieving equity, 3) intellectual property and access to… Continue Reading →

7 July 2022: Human Rights Council adopts resolution on right to health resolution with references delinkage, solidarity, global public good, and the transfer of technology and know-how

On Thursday, 7 July 2022, the 40th session of the Human Rights Council (HRC) adopted, by consensus, a resolution on Access to medicines, vaccines and other health products in the context of the right of everyone to the enjoyment of… Continue Reading →

KEI review of 62 COVID 19 contracts reveals 59 authorizations for non-voluntary use of third party patents under 28 USC 1498

Since the COVID 19 Pandemic began, there has been a spirited debate over patent rights, including a highly publicized 20 month debate over a proposed WTO waiver on intellectual property rights. During that time a handful of countries have taken… Continue Reading →

KEI letter to Roche requesting voluntary license to patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA)

This is a letter to Roche requesting a voluntary license to the patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA). KEI-Risdiplan-patent-license-request-8july2022 This was the August 5, 2022 response from Roche. Roche-Response-to-Risdiplam-license-request–5Aug2022 KEI wrote to Roche again on February… Continue Reading →